… of the terms biomarkers, PD-1, PD-U, CTLA-4, and checkpoint inhibitors in the title and the
… of influencing a subject's response of immune checkpoint inhibitors were selected. Priority …

… mutation serves as a novel biomarker correlated with a better response to ICI therapy. …
response to ICI therapy in clinical practice. As a consequence, biomarkers predicting response …

… PD-L1 expression in tumor cells/microenvironment has been correlated to response to
treatment with the PD-1 inhibitor and to date represents the only available biomarker of response …

… Long-term survival of stage IV melanoma patients has improved significantly with the
development of immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and …

… value of biomarkers for anti-CTLA-4 and anti-PD-1/PD-L1 as the most commonly used
checkpoint inhibitors. There are currently no reliable biomarkers capable of predicting responses …

… effective biomarkers to predict efficacy. Therefore, in this review, we systematically summarize
the possible biomarkers that can affect the efficacy of immune checkpoint inhibitors such …

… Key factors in biomarker development for immune checkpoint inhibitors therapy. … , predictive
biomarkers are largely required for anticipating the efficacy of immune checkpoint inhibitors. …

… Here, we would like to elaborate on the mechanism of checkpoint inhibitors. The immune
system generally recognizes and destroys cancer cells. If immunity becomes low, tumor cells …

… As robust biomarkers to predict clinical response and/or resistance remain elusive, the … ICI
response (and resistance) may not only identify novel predictive and/or prognostic biomarkers, …

Immune-checkpoint inhibition (ICI) treatments improve outcomes for metastatic melanoma;
however, > 60% of treated patients do not respond to ICI. Current biomarkers do not reliably …